Skip to content

Internet Buzzing About Protalix BioTherapeutics’ Orphan Drug Elelyso For Gaucher Disease (October 1, 2012)

October 2, 2012

         The Internet is buzzing about Protalix BioTherapeutics’ orphan drug Elelyso for Gaucher Disease (October 1, 2012) :

1)  SeekingAlpha.com October 1, 2012 Article titled,”Protalix Biotherapeutics: Eyes on Elelyso Sales & Advancing Pipeline” :

–  Marketing application submitted to the National Sanitary Vigilance Agency (ANVISA) of Brazil

–  Marketing application submitted to the Australian Therapeutics Goods Administration (TGA)

–  Gaucher Disease worldwide prevalence is 1/40,000; approximately 8,000 patients in US

–  Excellent analysis & comparison of the key players in the competitive Gaucher Disease market.

2)  ThePharmaLetter.com October 1, 2012 Article titled, “Protalix gains Israeli approval for Gaucher drug Elelyso” :

–  At USA launch, Elelyso costs $150,000/year of therapy

–  Genzyme’s Cerezyme costs $200,000/year of therapy

–  Shire plc’s Vpriv costs $170,000/year of therapy.

3)  CafePharma.com’s “Social Media Monitoring Page for Protalix BioTherapeutics”.

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: